OMERS ADMINISTRATION Corp Sells 4,400 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

OMERS ADMINISTRATION Corp reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,700 shares of the medical equipment provider’s stock after selling 4,400 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Lantheus were worth $1,405,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of LNTH. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $37,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $125,000. 99.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,109 shares of company stock valued at $6,016,046. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

NASDAQ LNTH opened at $79.78 on Friday. The firm has a market cap of $5.46 billion, a PE ratio of 13.27 and a beta of 0.23. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The stock’s 50 day simple moving average is $97.57 and its 200 day simple moving average is $93.51.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the company posted $1.69 EPS. The firm’s quarterly revenue was up .8% compared to the same quarter last year. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on LNTH. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, Truist Financial decreased their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus presently has an average rating of “Buy” and a consensus target price of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.